Education
About Us
Working with TipRanks
Follow Us
Elena Ridloff Insider Profile
4 Followers
Elena Ridloff, EVP & CFO at ACADIA Pharmaceuticals, holds 25.30K shares in Kronos Bio (Ticker: KRON), holds 10.55K shares in ACADIA Pharmaceuticals (Ticker: ACAD), holds ― shares in Kymera Therapeutics (Ticker: KYMR).
Elena Ridloff has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Elena Ridloff holds in companies
Most Profitable Insider Trade
The most profitable trade made by Elena Ridloff
Elena Ridloff's Trading History
ACADIA Pharmaceuticals
Apr 30, 2021
EVP & CFO
Uninformative Buy
45.57K
$185.31K
Kronos Bio
Jun 26, 2024
Director
Uninformative Buy
―
$24.28K
Kymera Therapeutics
―
Director
―
―
Sionna Therapeutics, Inc.
―
CFO & Head of Corp. Dev.
―
―
List of latest transactions for each holding click on a transaction to see Elena Ridloff's performance on stock
You May Also Like
Elena Ridloff insider profile FAQ
What is the percentage of profitable transactions made by Elena Ridloff?
The percentage of profitable transactions made by Elena Ridloff is ―.
What is the average return per transaction made by Elena Ridloff?
The average return per transaction made by Elena Ridloff is ―.
What stocks does Elena Ridloff hold?
Elena Ridloff holds: ACAD, KRON, KYMR, SION stocks.
What was Elena Ridloff’s latest transaction?
Elena Ridloff latest transaction was an Uninformative Buy of ―.
What was Elena Ridloff's most profitable transaction?
Elena Ridloff’s most profitable transaction was an Informative Buy of KRON stock on October 16, 2020. The return on the trade was -47.60%.
What is Elena Ridloff's role in ACADIA Pharmaceuticals?
Elena Ridloff's role in ACADIA Pharmaceuticals is EVP & CFO.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.